Core Viewpoint - Cofoe Medical's stock closed at 33.06 yuan on June 16, with a decline of 1.67%, resulting in a rolling PE ratio of 22.89 times and a total market capitalization of 6.913 billion yuan [1] Company Overview - Cofoe Medical Technology Co., Ltd. specializes in the research, production, sales, and service of medical devices, with key products including blood glucose systems, uric acid systems, blood pressure monitors, and various other medical instruments and supplies [2] - The company has received several accolades, including being recognized as a potential brand in the Chinese drug retail market for 2023-2024 and as a leading brand for assistive devices in Hunan Province [2] Financial Performance - In the first quarter of 2025, Cofoe Medical reported an operating revenue of 738 million yuan, a year-on-year decrease of 8.59%, and a net profit of 91.425 million yuan, down 9.68%, with a gross profit margin of 52.17% [2] Industry Comparison - The average PE ratio for the medical device industry is 49.56 times, with a median of 36.18 times, positioning Cofoe Medical at the 50th rank within the industry [1][3] - Cofoe Medical's PE ratio is significantly lower than the industry average and median, indicating potential undervaluation compared to peers [3]
可孚医疗收盘下跌1.67%，滚动市盈率22.89倍，总市值69.13亿元